ESR1 Coalteration Treatment Resistance Does Not Impact Lasofoxifene/Abemaciclib Efficacy in ESR1+ Metastatic Breast Cancer

The presence of ESR1 coabnormalities, including TP53 and PIK3CA mutations, and CCND1 and FGFR1 amplification, did not demonstrate a negative impact on the efficacy with lasofoxifene and abemaciclib in patients with estrogen receptor–positive, ESR1-mutant metastatic breast cancer.

Related Keywords

San Antonio ,Texas ,United States ,Dsenthil Damodaran ,University Of Texas Md Anderson Cancer Center ,Antonio Breast Cancer Symposium ,Cancer Center ,Metastatic Breast Cancer ,Breast Cancer ,Toxicity ,San Antonio Breast Cancer Symposium ,Sabcs ,Phase 2 Elaine Study ,Esr1 Coalteration ,Lasofoxifene ,Abemaciclib ,Tp53 And Pik3ca ,Estrogen Receptor Positive ,